Twist Bioscience (NASDAQ:TWST) PT Lowered to $30.00 at SVB Leerink

Twist Bioscience (NASDAQ:TWSTGet Rating) had its price objective reduced by SVB Leerink from $45.00 to $30.00 in a research report sent to investors on Monday, Marketbeat.com reports. SVB Leerink currently has a market perform rating on the stock.

Other equities research analysts also recently issued reports about the stock. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $45.00 and set an overweight rating for the company in a research note on Thursday, October 6th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $43.00 to $56.00 in a research note on Monday, August 8th.

Twist Bioscience Trading Up 1.3 %

TWST opened at $25.53 on Monday. Twist Bioscience has a 1-year low of $23.90 and a 1-year high of $99.74. The company has a market cap of $1.44 billion, a P/E ratio of -6.33 and a beta of 1.15. The company has a fifty day moving average price of $32.37 and a two-hundred day moving average price of $36.79.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 8,514 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $37.43, for a total transaction of $318,679.02. Following the sale, the senior vice president now directly owns 14,199 shares in the company, valued at approximately $531,468.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 9,211 shares of company stock worth $341,371 over the last three months. 3.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently made changes to their positions in the stock. Capital Impact Advisors LLC boosted its stake in shares of Twist Bioscience by 6.3% in the 3rd quarter. Capital Impact Advisors LLC now owns 19,177 shares of the company’s stock valued at $487,000 after purchasing an additional 1,132 shares in the last quarter. Sandia Investment Management LP purchased a new stake in shares of Twist Bioscience in the 3rd quarter worth about $88,000. BNP Paribas Arbitrage SNC lifted its position in shares of Twist Bioscience by 593.0% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 89,246 shares of the company’s stock worth $3,145,000 after purchasing an additional 76,367 shares during the period. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience in the 3rd quarter worth about $1,978,000. Finally, Two Sigma Investments LP bought a new position in shares of Twist Bioscience in the 3rd quarter worth about $2,995,000.

About Twist Bioscience

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.